Generalized Myasthenia Gravis Market Research
What is Generalized Myasthenia Gravis (gMG)?
Myasthenia gravis (gMG) is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscles. gMG affects the voluntary muscles of the body, such as those that control the eyes, mouth, throat and limbs. This results in weakness of the skeletal muscles, which can cause difficulty with leading a normal active life. Disease onset can occur at any age but is seen more frequently in younger women (age 20 and 30) and older men (age 50 and older). While there is no cure for gMG, treatment options include medication, surgery, or a combination of approaches.
Spherix Global Insights – Neurology – Generalized Myasthenia Gravis Market Research
Spherix’s Neurology team covers the gMG market in our Market Dynamix™, Launch Dynamix™, and Patient Chart Dynamix™ services. Spherix’s has the following studies publishing this year covering gMG:
- Launch Dynamix™: Vyvgart (argenx) and Ultomiris (Alexion) in Generalized Myasthenia Gravis (US)
- Launch Dynamix™: Vyvgart Hytrulo and Rystiggo in Generalized Myasthenia Gravis (US)
- Launch Dynamix™: Zilucoplan (UCB) in Generalized Myasthenia Gravis (US)*
- Market Dynamix™: Generalized Myasthenia Gravis (US)
- Market Dynamix™: Generalized Myasthenia Gravis (EU)
- Patient Chart Dynamix™: Generalized Myasthenia Gravis (US)
*Pending approvals and launch
Spherix’s Market Dynamix™ service is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Spherix’s Patient Chart Dynamix™ service includes patient-level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.
Follow Spherix Neurology on Social Media
Follow us for neurology industry news, insights & analysis:
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:
Spherix’s 2023 Generalized Myasthenia Gravis (gMG) Services: